Embarking on a groundbreaking journey, fintech start-up Evorest is transforming the landscape of rental deposits. The company specializes in the digital management of rental deposits, offering tenants a unique opportunity to invest their funds digitally in low-cost funds, providing an alternative to traditional low-interest accounts. Guiding Evorest through this innovative venture is VISCHER, a legal […]
Swiss law firm Bratschi played a pivotal role in advising the shareholders of Precipart, a prominent manufacturer specializing in precision components for the medical device and aerospace sectors, concerning a significant investment from KKR. KKR
Baker McKenzie Switzerland played a pivotal role in advising Mateco group on its acquisition of Maltech Holding and subsidiaries, the prominent Swiss market leader in rentable lifting platforms. This acquisition marks a significant stride in
In a strategic move to advance innovation in the Infection Control and Life Science domain, Metall Zug and Miele have inked a transformative agreement. The deal outlines the creation of a new joint venture, where
In a strategic move, Ringier has successfully acquired all shares in the former Swiss joint venture, Ringier Axel Springer Schweiz (RASCH), from Axel Springer. The joint venture, established in 2016, has been a collaborative effort until
Kohlberg Kravis Roberts (KKR) makes a significant investment into the Precipart Group, a renowned contract manufacturer of high-precision components to the medical, aerospace and industrial markets. KKR plans to support the company in its continued
The Danish company Kimbrer Computer, a supplier of used IT equipment and a Trill Impact portfolio company, has acquired Renewtech, a provider of circular IT services and networking solutions. The acquisition of Renewtech also marks
In a groundbreaking move, Boehringer Ingelheim has sealed the deal to acquire T3 Pharmaceuticals, a dynamic Swiss biotech company, for a staggering amount of up to 450 million CHF. This strategic move signals a major leap
Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, has announced the completion of its oversubscribed Series C equity financing raising EUR 67.5m (USD 72m) from a syndicate
LASCCO, a biomedical-technology company, and Abionic, a nanotechnology company, both based at the Biopôle of Lausanne, entered into a licensing agreement with Fapon Biotech, a global leading life sciences company, based in Dongguan (China)
